JP2025515165A - 改変されたXa因子ポリペプチドおよび使用方法 - Google Patents

改変されたXa因子ポリペプチドおよび使用方法 Download PDF

Info

Publication number
JP2025515165A
JP2025515165A JP2024565175A JP2024565175A JP2025515165A JP 2025515165 A JP2025515165 A JP 2025515165A JP 2024565175 A JP2024565175 A JP 2024565175A JP 2024565175 A JP2024565175 A JP 2024565175A JP 2025515165 A JP2025515165 A JP 2025515165A
Authority
JP
Japan
Prior art keywords
polypeptide
factor
seq
nucleic acid
apixaban
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024565175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515165A5 (https=
Inventor
ズベン イー. サウナ,
ウォイチェフ ジャンコウスキ,
ナンシー イー. ヘルナンデス,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2025515165A publication Critical patent/JP2025515165A/ja
Publication of JP2025515165A5 publication Critical patent/JP2025515165A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21006Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024565175A 2022-05-06 2023-05-05 改変されたXa因子ポリペプチドおよび使用方法 Pending JP2025515165A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263339230P 2022-05-06 2022-05-06
US63/339,230 2022-05-06
PCT/US2023/066676 WO2023215879A1 (en) 2022-05-06 2023-05-05 Modified factor xa polypeptides and methods of use

Publications (2)

Publication Number Publication Date
JP2025515165A true JP2025515165A (ja) 2025-05-13
JP2025515165A5 JP2025515165A5 (https=) 2026-04-28

Family

ID=87474126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024565175A Pending JP2025515165A (ja) 2022-05-06 2023-05-05 改変されたXa因子ポリペプチドおよび使用方法

Country Status (4)

Country Link
US (1) US20250302927A1 (https=)
EP (1) EP4519431A1 (https=)
JP (1) JP2025515165A (https=)
WO (1) WO2023215879A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019246094A1 (en) * 2018-06-19 2019-12-26 Portola Pharmaceuticals, Inc. Antidotes to factor xa inhibitors

Also Published As

Publication number Publication date
EP4519431A1 (en) 2025-03-12
US20250302927A1 (en) 2025-10-02
WO2023215879A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
CA2737094C (en) Factor ix polypeptide mutant, its uses and a method for its production
JP6000353B2 (ja) プラスミノーゲンおよびプラスミンの変異体
CA2850603C (en) Compositions and methods for modulating hemostasis
KR101672108B1 (ko) 패혈증의 치료 및/또는 개선을 위한 의약
CN112126636B (zh) 一种高活性凝血因子XI突变体Ala570Thr
JPWO1992000325A1 (ja) 抗血液凝固活性を有するポリペプチド
MX2008006313A (es) Metodos y composiciones para modular la hemostasia.
CN109260462B (zh) 一种凝血酶原突变体蛋白及其编码核酸的应用
US10676731B2 (en) Compositions and methods for modulating factor IX function
EP2869834B1 (en) Plasminogen activator mutants as anti-fibrinolytic agents
JP2025515165A (ja) 改変されたXa因子ポリペプチドおよび使用方法
CN108517009A (zh) Sj13多肽及其在制备抗血栓药物中的应用
JP6629744B2 (ja) 第Xa因子の半減期を延ばす組成物および方法
WO2016057306A1 (en) Rho associated kinase (rock) inhibitors and their use in treating disease
JP6298582B2 (ja) トロンビン生成を調節する組成物および方法
JP2023505208A (ja) 第viii因子の機能を調節するための組成物および方法
EP3096779A1 (en) Compositions and methods for treating intracerebral hemorrhage
WO2010078469A2 (en) Sand fly salivary proteins as novel factor xa inhibitors and methods of use
HK40088231A (en) Factor ix polypeptide mutant, its uses and a method for its production
HK40026244A (en) Recombinant protein and fragments thereof, method for producing said recombinant protein, synthetic gene and use of recombinant protein
HK1130209B (en) Therapeutic and/or ameliorating agent for disseminated intravascular coagulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260420